Literature DB >> 7870179

Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP.

J R Lundblad1, R P Kwok, M E Laurance, M L Harter, R H Goodman.   

Abstract

The 265K nuclear protein CBP was initially identified as a co-activator for the protein kinase A (PKA)-phosphorylated form of the transcription factor CREB. The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown. Here, we show that CBP and p300 have similar binding affinity for the PKA-phosphorylated form of CREB, and that p300 can substitute for CBP in potentiating CREB-activated gene expression. We find that E1A binds to CBP through a domain conserved with p300 and represses the CREB-dependent co-activator functions of both CBP and p300. Our results indicate that the gene repression and cell immortalization functions associated with E1A involve the inactivation of a family of related proteins that normally participate in second-messenger-regulated gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7870179     DOI: 10.1038/374085a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  180 in total

1.  MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein.

Authors:  P Ernst; J Wang; M Huang; R H Goodman; S J Korsmeyer
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300.

Authors:  M J O'Connor; H Zimmermann; S Nielsen; H U Bernard; T Kouzarides
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Synergism with germ line transcription factor Oct-4: viral oncoproteins share the ability to mimic a stem cell-specific activity.

Authors:  A Brehm; K Ohbo; W Zwerschke; V Botquin; P Jansen-Dürr; H R Schöler
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

5.  The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus.

Authors:  D Zerby; C J Chen; E Poon; D Lee; R Shiekhattar; P M Lieberman
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.

Authors:  M A Cotter; E S Robertson
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

7.  The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation.

Authors:  K E Scoggin; A Ulloa; J K Nyborg
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

8.  Loss of p19(ARF) eliminates the requirement for the pRB-binding motif in simian virus 40 large T antigen-mediated transformation.

Authors:  H H Chao; A M Buchmann; J A DeCaprio
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

9.  AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Authors:  Pengfei Li; Heehyoung Lee; Shaodong Guo; Terry G Unterman; Guido Jenster; Wenlong Bai
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

10.  Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits.

Authors:  Ana M M Oliveira; Marcelo A Wood; Conor B McDonough; Ted Abel
Journal:  Learn Mem       Date:  2007-08-29       Impact factor: 2.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.